Trial Profile
A safety and efficacy study of Ezogabine for patients with KCNQ2 encephalopathy
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2018
Price :
$35
*
At a glance
- Drugs Retigabine (Primary)
- Indications Encephalopathy
- Focus Adverse reactions; Therapeutic Use
- 03 Jan 2018 New trial record
- 05 Dec 2017 Results assessing safety and efficacy presented at the 71st Annual Meeting of the American Epilepsy Society